INTRODUCTION METHODS
The study was opened to patients with histopathologicaly confirmed well differentiated neuroendocrine tumours. All patients were treated with PRRT (4 to 5 cycles repeated every 6 do 12 weeks). After the last cycle of PRRT treatment response was evaluated with scintigraphic, radiological and biochemical examination. Thereafter patients were randomly assigned either to treatment with somatostatin analouges or observation group (2:1 randomisation). Initiation of next line of therapy was left to discretion of treating physician.
Patients were followed-up at 4-12 months intervals with radiological examinations (CT or MRI) and receptors scintigraphy. Median time to progression was measured from the start of PRRT treatment till the day of disease progression confirmed in radiological or scintigraphic examination. One hundred twenty five with well differentiated neuroendocrine tumours were included. At the time of randomisation none of the patient suffered from carcinoid syndrome.
RESULTS
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After completion of radiolabelled somatostatin analogues therapy 81 patients were randomly assigned to somatostatin analogues and 44 to observation group.
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Fig 2. Results of PRRT according to RECIST criteria
The median follow-up the calculated from the start of PRRT was 44 months for the whole group of patients. During that time 81 (65%) progressed.
There was a trend to longer progression free survival in SSA group, however, the difference was statistically insignificant (fig.3 ). Preliminary results suggest that consolidation treatment with SA did not improve results of PRRT. However, larger number of patients and longer follow-up is necessary.
